Nexalin Technology Inc. (NXL): Price and Financial Metrics

Nexalin Technology Inc. (NXL): $0.89

-0.03 (-3.55%)

POWR Rating

Component Grades








NXL Price/Volume Stats

Current price $0.89 52-week high $3.23
Prev. close $0.92 52-week low $0.65
Day low $0.84 Volume 8,731
Day high $0.90 Avg. volume 46,921
50-day MA $0.83 Dividend yield N/A
200-day MA $0.00 Market Cap 6.48M

NXL Stock Price Chart Interactive Chart >

NXL Latest News Stream

Event/Time News Detail
Loading, please wait...

NXL Latest Social Stream

Loading social stream, please wait...

View Full NXL Social Stream

Latest NXL News From Around the Web

Below are the latest news stories about NEXALIN TECHNOLOGY INC that investors may wish to consider to help them evaluate NXL as an investment opportunity.

Nexalin Technology Full Year 2022 Earnings: US$0.30 loss per share (vs US$1.43 loss in FY 2021)

Nexalin Technology ( NASDAQ:NXL ) Full Year 2022 Results Key Financial Results Revenue: US$1.32m (up by US$1.18m from...

Yahoo | March 30, 2023

Nexalin Technology Provides 2022 Year-End Business Update

HOUSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided a business update for the year ended December 31, 2022. Mark White, CEO of Nexalin Technology stated, “Nexalin has made significant progress towards commencing clinical trials of our Gen-2 and Gen-3 neurostimulation devices in the United States. Nexalin’s enhanced neurostimulation devices combine innovation, frequencies and algorithms to provide an unprecedented s

Yahoo | March 27, 2023

Nexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory

HOUSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory. Mr. Nketiah is an expert in regulatory affairs, as well as clinical and quality assurance, specializing in US FDA and international regulatory approvals, with over 23 years of experience working directly with the FDA in the medical device and life sciences industries,

Yahoo | January 24, 2023

Nexalin Technology CEO Provides Letter to Shareholders

HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the following business update and letter to shareholders from its Chief Executive Officer, Mark White: To our valued shareholders, I would like to thank all of you for your tremendous support, as we look towards a very bright future in 2023 and beyond. Nexalin has built a solid foundation, grounded in strong intellectual property, and backed by growing clinical da

Yahoo | January 5, 2023

Nexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder

The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep Treatment effect persisted after four months of follow-up HOUSTON, TX, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the publication of a white paper, titled, “A case report of Nexalin ADI in the treatment of somatic symptoms of anxiety,

Yahoo | November 14, 2022

Read More 'NXL' Stories Here

NXL Price Returns

1-mo 5.99%
3-mo -10.09%
6-mo -59.73%
1-year N/A
3-year N/A
5-year N/A
YTD 18.83%
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!